Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.84
REGN's Cash to Debt is ranked higher than
59% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. REGN: 1.84 )
REGN' s 10-Year Cash to Debt Range
Min: 0.57   Max: No Debt
Current: 1.84

Equity to Asset 0.68
REGN's Equity to Asset is ranked higher than
73% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. REGN: 0.68 )
REGN' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.93
Current: 0.68

0.18
0.93
Interest Coverage 16.37
REGN's Interest Coverage is ranked higher than
53% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 16.37 )
REGN' s 10-Year Interest Coverage Range
Min: 0.46   Max: 16.37
Current: 16.37

0.46
16.37
F-Score: 4
Z-Score: 23.39
M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 30.56
REGN's Operating margin (%) is ranked higher than
95% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. REGN: 30.56 )
REGN' s 10-Year Operating margin (%) Range
Min: -554.63   Max: 187.97
Current: 30.56

-554.63
187.97
Net-margin (%) 12.74
REGN's Net-margin (%) is ranked higher than
90% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. REGN: 12.74 )
REGN' s 10-Year Net-margin (%) Range
Min: -565.66   Max: 54.43
Current: 12.74

-565.66
54.43
ROE (%) 15.53
REGN's ROE (%) is ranked higher than
94% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. REGN: 15.53 )
REGN' s 10-Year ROE (%) Range
Min: -75.77   Max: 86.68
Current: 15.53

-75.77
86.68
ROA (%) 10.43
REGN's ROA (%) is ranked higher than
94% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. REGN: 10.43 )
REGN' s 10-Year ROA (%) Range
Min: -28.05   Max: 44.08
Current: 10.43

-28.05
44.08
ROC (Joel Greenblatt) (%) 55.36
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. REGN: 55.36 )
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -214.91   Max: 168.03
Current: 55.36

-214.91
168.03
Revenue Growth (%) 50.60
REGN's Revenue Growth (%) is ranked higher than
97% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. REGN: 50.60 )
REGN' s 10-Year Revenue Growth (%) Range
Min: -25.3   Max: 81.1
Current: 50.6

-25.3
81.1
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

REGN Guru Trades in Q4 2013

Steven Cohen 28,304 sh (+1893.24%)
Vanguard Health Care Fund 1,412,100 sh (unchged)
Joel Greenblatt Sold Out
Frank Sands 3,732,680 sh (-1.18%)
Jim Simons 70,062 sh (-71.92%)
» More
Q1 2014

REGN Guru Trades in Q1 2014

Andreas Halvorsen 1,051,800 sh (New)
Ron Baron 6,084 sh (New)
Paul Tudor Jones 893 sh (New)
Steven Cohen 65,232 sh (+130.47%)
Vanguard Health Care Fund 1,743,468 sh (+23.47%)
Frank Sands 4,012,062 sh (+7.48%)
Jim Simons Sold Out
» More
Q2 2014

REGN Guru Trades in Q2 2014

Joel Greenblatt 881 sh (New)
Ray Dalio 18,400 sh (New)
Mario Gabelli 2,295 sh (New)
Jim Simons 2,862 sh (New)
Andreas Halvorsen 2,963,456 sh (+181.75%)
Vanguard Health Care Fund 2,795,500 sh (+60.34%)
Frank Sands 4,907,362 sh (+22.32%)
Ron Baron 7,109 sh (+16.85%)
Steven Cohen 14,500 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2014

REGN Guru Trades in Q3 2014

Ken Fisher 583 sh (New)
Paul Tudor Jones 2,499 sh (New)
Jim Simons 26,562 sh (+828.09%)
Steven Cohen 23,600 sh (+62.76%)
Joel Greenblatt 1,410 sh (+60.05%)
Frank Sands 4,967,466 sh (+1.22%)
Vanguard Health Care Fund 2,795,500 sh (unchged)
Ron Baron 7,109 sh (unchged)
Mario Gabelli 2,190 sh (-4.58%)
Andreas Halvorsen 1,080,682 sh (-63.53%)
Ray Dalio 1,600 sh (-91.3%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-09-30 Reduce -63.53%2.35%$296.41 - $364.41 $ 415.8424%1080682
Ray Dalio 2014-09-30 Reduce -91.3%0.04%$296.41 - $364.41 $ 415.8424%1600
Joel Greenblatt 2014-09-30 Add 60.05%$296.41 - $364.41 $ 415.8424%1410
Ken Fisher 2014-09-30 New Buy$296.41 - $364.41 $ 415.8424%583
Andreas Halvorsen 2014-06-30 Add 181.75%2.39%$277.29 - $313.74 $ 415.8440%2963456
Vanguard Health Care Fund 2014-06-30 Add 60.34%0.79%$277.29 - $313.74 $ 415.8440%2795500
Frank Sands 2014-06-30 Add 22.32%0.64%$277.29 - $313.74 $ 415.8440%4907362
Ray Dalio 2014-06-30 New Buy0.04%$277.29 - $313.74 $ 415.8440%18400
Mario Gabelli 2014-06-30 New Buy$277.29 - $313.74 $ 415.8440%2295
Joel Greenblatt 2014-06-30 New Buy$277.29 - $313.74 $ 415.8440%881
Andreas Halvorsen 2014-03-31 New Buy1.3%$267.62 - $347.62 $ 415.8435%1051800
Vanguard Health Care Fund 2014-03-31 Add 23.47%0.29%$267.62 - $347.62 $ 415.8436%1743468
Frank Sands 2014-03-31 Add 7.48%0.22%$267.62 - $347.62 $ 415.8435%4012062
Ron Baron 2014-03-31 New Buy0.01%$267.62 - $347.62 $ 415.8435%6084
Joel Greenblatt 2013-12-31 Sold Out 0.03%$261.88 - $313.67 $ 415.8445%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA
According to GuruFocus Insider Data, the largest insider sells during the past week were: Microsoft Corp, Regeneron Pharmaceuticals Inc., Activision Blizzard Inc. and Mid-America Apartment Communities. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 135.10
REGN's P/E(ttm) is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 135.10 )
REGN' s 10-Year P/E(ttm) Range
Min: 9.85   Max: 135.06
Current: 135.1

9.85
135.06
P/B 16.65
REGN's P/B is ranked higher than
61% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. REGN: 16.65 )
REGN' s 10-Year P/B Range
Min: 1.43   Max: 26.42
Current: 16.65

1.43
26.42
P/S 17.33
REGN's P/S is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. REGN: 17.33 )
REGN' s 10-Year P/S Range
Min: 2.07   Max: 27.97
Current: 17.33

2.07
27.97
PFCF 83.50
REGN's PFCF is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 83.50 )
REGN' s 10-Year PFCF Range
Min: 9.29   Max: 2102
Current: 83.5

9.29
2102
EV-to-EBIT 52.11
REGN's EV-to-EBIT is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 52.11 )
REGN' s 10-Year EV-to-EBIT Range
Min: -106.3   Max: 2827.2
Current: 52.11

-106.3
2827.2
Shiller P/E 354.99
REGN's Shiller P/E is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 354.99 )
REGN' s 10-Year Shiller P/E Range
Min: 274.54   Max: 1527
Current: 354.99

274.54
1527
Current Ratio 5.36
REGN's Current Ratio is ranked higher than
75% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. REGN: 5.36 )
REGN' s 10-Year Current Ratio Range
Min: 2.17   Max: 20.69
Current: 5.36

2.17
20.69
Quick Ratio 5.07
REGN's Quick Ratio is ranked higher than
75% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. REGN: 5.07 )
REGN' s 10-Year Quick Ratio Range
Min: 2.17   Max: 20.5
Current: 5.07

2.17
20.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 101.18
REGN's Price/Net Current Asset Value is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. REGN: 101.18 )
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.18   Max: 256.27
Current: 101.18

3.18
256.27
Price/Tangible Book 16.64
REGN's Price/Tangible Book is ranked higher than
66% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. REGN: 16.64 )
REGN' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 22
Current: 16.64

0.86
22
Price/DCF (Projected) 19.02
REGN's Price/DCF (Projected) is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 19.02 )
REGN' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 240.67
Current: 19.02

14.99
240.67
Price/Median PS Value 1.65
REGN's Price/Median PS Value is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. REGN: 1.65 )
REGN' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 5.04
Current: 1.65

0.21
5.04
Price/Graham Number 9.69
REGN's Price/Graham Number is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 9.69 )
REGN' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 8.4
Current: 9.69

1.24
8.4
Earnings Yield (Greenblatt) 1.90
REGN's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. REGN: 1.90 )
REGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 24.9
Current: 1.9

1.3
24.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Regeneron Pharmaceuticals Inc was incorporated in January 1988 in the State of New York. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 395,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 54,000 liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.
» More Articles for REGN

Headlines

Articles On GuruFocus.com
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
Insiders Are Buying Ophthotech Oct 08 2013 
Weekly Top Insider Sells: REGN May 27 2013 
comment on REGN Mar 06 2013 
Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 

More From Our Partners
Amgen Claims It All Nov 21 2014 - SEEKINGALPHA

More From Other Websites
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 26 2014
Cramer: Workday, Netflix, Amazon Struggle as Momentum Lags Nov 25 2014
Jim Cramer's Top Stock Picks: CSCO LB REGN AAPL YHOO Nov 25 2014
Jim Cramer's 'Mad Money' Recap: Here's Where Money Managers Should Put Their Money Nov 24 2014
Cramer: Not too late to buy Regeneron Nov 24 2014
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 21 2014
UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts Nov 21 2014
Fighting kids' cancer, one voucher at a time Nov 21 2014
New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014
Sanofi touts new drugs but diabetes outlook disappoints Nov 20 2014
Regeneron & Sanofi Present Positive Data on PCSK9 Drug Nov 20 2014
Gilead to Buy Knight Therapeutics' Priority Review Voucher Nov 20 2014
Regeneron Shares Could Reach $450 Nov 20 2014
Sanofi's Bullish Pipeline Forecast Underwhelms Street Nov 20 2014
Sanofi eyes more than $38 bln from new drugs after CEO exit Nov 20 2014
The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Nov 20 2014
Sanofi, Regeneron eczema drug gets FDA fast-track designation Nov 20 2014
Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in... Nov 20 2014
The Forbes Healthcare Summit 2014: The Agenda Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK